Ustekinumab in Crohn’s disease: evidence to date and place in therapy-Reference-Cited by-同舟云学术

Ustekinumab in Crohn’s disease: evidence to date and place in therapy

Published:2016-07 Issue:4 Volume:7 Page:208-214
ISSN:2040-6223
Container-title:Therapeutic Advances in Chronic Disease
language:en
Short-container-title:Therapeutic Advances in Chronic Disease

Author:

Engel Tal¹,Kopylov Uri²

Affiliation:

1. Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel

2. Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, 52621, Israel

Abstract

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.

Publisher

SAGE Publications

Subject

Medicine (miscellaneous)

Link

http://journals.sagepub.com/doi/pdf/10.1177/2040622316653306

Reference46 articles.

1. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

2. Demyelination in a patient receiving ustekinumab for refractory Crohn's disease: Figure 1

3. Battat R., Kopylov U., Bessissow T., Bitton A., Cohen A., Martel M. (2015) Association of ustekinumab trough concentrations with clinical, biochemical and endoscopic outcomes. European Crohn’s and Colitis Organisation Congress, 16–19 March, Amsterdam, The Netherlands. (DDW 2015 abstract).

4. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study

5. Neuroimmunology of the gut: physiology, pathology, and pharmacology

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying hub genes in response to ustekinumab and the impact of ustekinumab treatment on fibrosis in Crohn’s disease;Frontiers in Immunology;2024-05-22

2. Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease;Frontiers in Medicine;2023-07-24

3. Modern drug discovery for inflammatory bowel disease: The role of computational methods;World Journal of Gastroenterology;2023-01-14

4. Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study;Therapeutic Advances in Gastroenterology;2023-01

5. The treatment of inflammatory bowel disease with monoclonal antibodies in Asia;Biomedicine & Pharmacotherapy;2023-01